The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
In an interview with CancerNetwork®, Deepu Madduri, MD, assistant professor of Medicine (Hematology and Medical Oncology), associate director of Cellular Therapy Service, and director of Clinical Operations with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discussed the most influential multiple myeloma research that came out of 2020.
At the ASH [Annual Meeting & Exposition] this year, the most influential research, as you saw, were [about] bispecific [agents] or CAR T-cell therapies, right? We’re seeing a lot of changes in immune regulation [regarding] how the immune cells are working and understanding how to use those to target and attack the myeloma cells. There’s going to be a combination of trials and combination therapies that are really going to come up [to the front-line setting to determine] if that will benefit the patients.